Insulet Corp. (PODD) EV/EBIT Ratio: 21.53x
Is Insulet Corp.’s EV/EBIT ratio high or low?
Insulet Corp.'s EV/EBIT ratio of 21.53x is 88% below its 5-year average of 184.54x, near the low end of its 5-year range (20.16x–876.85x).
As of Thursday, June 25, 2026. 52.75% below its 12-month average of 45.57x.
PODD EV/EBIT Ratio Chart
PODD Average EV/EBIT Ratio Chart
PODD Current vs Average EV/EBIT Ratio Chart
PODD EV/EBIT Ratio Metrics
EV/EBIT RATIO
21.53x
EV/EBIT RATIO AVG TTM
45.57x
EV/EBIT RATIO AVG 3Y
59.31x
EV/EBIT RATIO AVG 5Y
138.52x
EV/EBIT RATIO AVG 10Y
N/A
EV/EBIT RATIO AVG 15Y
N/A
EV/EBIT RATIO AVG 20Y
N/A
CURRENT VS TTM AVG
-52.75%
CURRENT VS 3Y AVG
-63.70%
CURRENT VS 5Y AVG
-84.46%
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
PODD Competitors' EV/EBIT Ratio
| NAME | MARKET CAP | EV/EBIT RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Insulet Corp. (PODD) | $10.31B | 21.53x | 45.57x | 59.31x | 138.52x |
| Walgreens Boots Alliance, Inc. (WBA)vs › | $10.37B | N/A | 25.59x | 34.39x | 25.01x |
| Baxter International Inc. (BAX)vs › | $10.87B | N/A | 442.63x | 243.35x | 134.31x |
| Charles River Laboratories International, Inc. (CRL)vs › | $9.73B | 26.91x | 61.71x | 38.61x | 35.02x |
| Henry Schein, Inc. (HSIC)vs › | $9.38B | 17.23x | 15.79x | 16.36x | 15.54x |
| Revvity, Inc. (RVTY)vs › | $11.78B | 39.71x | 35.68x | 38.80x | 31.76x |
| Align Technology, Inc. (ALGN)vs › | $12.24B | 19.09x | 19.24x | 26.19x | 30.99x |
| Solventum Corporation (SOLV)vs › | $13.01B | 8.30x | 20.42x | 17.27x | 17.27x |
| Bio-Rad Laboratories, Inc. (BIO)vs › | $7.57B | 35.16x | 38.24x | 32.89x | 33.24x |
| Oscar Health, Inc. (OSCR)vs › | $7.56B | 494.23x | 194.08x | 110.73x | 110.73x |
Insulet Corp. EV/EBIT Ratio Formula & Definition
EV/EBIT = Enterprise Value / EBIT (TTM)
Enterprise value to EBIT compares total company value to operating earnings, accounting for depreciation unlike EV/EBITDA.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
Insulet Corp. EV/EBIT Ratio FAQ
- What is the EV/EBIT ratio for Insulet Corp. (PODD)?
- The EV/EBIT ratio for PODD stock is 21.53x.
- Is Insulet Corp.'s EV/EBIT ratio high or low?
- Insulet Corp.'s EV/EBIT ratio of 21.53x is 88% below its 5-year average of 184.54x, near the low end of its 5-year range (20.16x–876.85x).
- What is the TTM average EV/EBIT ratio for Insulet Corp. (PODD)?
- The TTM average EV/EBIT ratio for PODD stock is 45.57x.
- What is the 3Y average EV/EBIT ratio for Insulet Corp. (PODD)?
- The 3Y average EV/EBIT ratio for PODD stock is 59.31x.
- What is the 5Y average EV/EBIT ratio for Insulet Corp. (PODD)?
- The 5Y average EV/EBIT ratio for PODD stock is 138.52x.
Insulet Corp. EV/EBIT Ratio History
| DATE | EV/EBIT RATIO |
|---|---|
| 2026-06-24 | 21.53x |
| 2026-06-23 | 20.84x |
| 2026-06-22 | 20.16x |
| 2026-06-18 | 21.10x |
| 2026-06-17 | 20.79x |
| 2026-06-16 | 21.36x |
| 2026-06-15 | 21.43x |
| 2026-06-12 | 21.64x |
| 2026-06-11 | 21.57x |
| 2026-06-10 | 21.78x |
| 2026-06-09 | 23.01x |
| 2026-06-08 | 21.89x |
| 2026-06-05 | 22.13x |
| 2026-06-04 | 21.19x |
| 2026-06-03 | 20.76x |
| 2026-06-02 | 20.64x |
| 2026-06-01 | 21.42x |
| 2026-05-29 | 20.98x |
| 2026-05-28 | 20.67x |
| 2026-05-27 | 21.13x |
| 2026-05-26 | 22.21x |
| 2026-05-22 | 22.36x |
| 2026-05-21 | 22.64x |
| 2026-05-20 | 22.60x |
| 2026-05-19 | 22.32x |
| 2026-05-18 | 22.03x |
| 2026-05-15 | 21.33x |
| 2026-05-14 | 21.50x |
| 2026-05-13 | 21.52x |
| 2026-05-12 | 22.84x |
| 2026-05-11 | 22.26x |
| 2026-05-08 | 22.26x |
| 2026-05-07 | 23.12x |
| 2026-05-06 | 21.86x |
| 2026-05-05 | 25.69x |
| 2026-05-04 | 26.26x |
| 2026-05-01 | 26.81x |
| 2026-04-30 | 26.38x |
| 2026-04-29 | 24.57x |
| 2026-04-28 | 27.98x |
| 2026-04-27 | 28.79x |
| 2026-04-24 | 28.97x |
| 2026-04-23 | 29.37x |
| 2026-04-22 | 29.58x |
| 2026-04-21 | 29.39x |
| 2026-04-20 | 30.66x |
| 2026-04-17 | 31.09x |
| 2026-04-16 | 30.75x |
| 2026-04-15 | 30.90x |
| 2026-04-14 | 30.75x |
| 2026-04-13 | 30.20x |
| 2026-04-10 | 30.07x |
| 2026-04-09 | 30.44x |
| 2026-04-08 | 31.05x |
| 2026-04-07 | 30.90x |
| 2026-04-06 | 31.05x |
| 2026-04-02 | 31.17x |
| 2026-04-01 | 31.58x |
| 2026-03-31 | 32.00x |
| 2026-03-30 | 31.72x |
| 2026-03-27 | 31.76x |
| 2026-03-26 | 33.23x |
| 2026-03-25 | 32.92x |
| 2026-03-24 | 34.33x |
| 2026-03-23 | 34.57x |
| 2026-03-20 | 34.57x |
| 2026-03-19 | 34.80x |
| 2026-03-18 | 35.05x |
| 2026-03-17 | 35.08x |
| 2026-03-16 | 34.21x |
| 2026-03-13 | 33.49x |
| 2026-03-12 | 35.91x |
| 2026-03-11 | 36.32x |
| 2026-03-10 | 36.23x |
| 2026-03-09 | 36.55x |
| 2026-03-06 | 36.05x |
| 2026-03-05 | 36.63x |
| 2026-03-04 | 36.93x |
| 2026-03-03 | 36.77x |
| 2026-03-02 | 37.31x |
| 2026-02-27 | 37.48x |
| 2026-02-26 | 38.21x |
| 2026-02-25 | 37.71x |
| 2026-02-24 | 37.28x |
| 2026-02-23 | 37.89x |
| 2026-02-20 | 36.78x |
| 2026-02-19 | 37.85x |
| 2026-02-18 | 39.19x |
| 2026-02-17 | 40.47x |
| 2026-02-13 | 39.89x |
| 2026-02-12 | 39.58x |
| 2026-02-11 | 41.20x |
| 2026-02-10 | 41.45x |
| 2026-02-09 | 40.34x |
| 2026-02-06 | 39.75x |
| 2026-02-05 | 39.95x |
| 2026-02-04 | 41.26x |
| 2026-02-03 | 41.26x |
| 2026-02-02 | 42.13x |
| 2026-01-30 | 42.00x |
| 2026-01-29 | 41.88x |
| 2026-01-28 | 42.39x |
| 2026-01-27 | 43.47x |
| 2026-01-26 | 44.51x |
| 2026-01-23 | 44.55x |
| 2026-01-22 | 45.91x |
| 2026-01-21 | 46.71x |
| 2026-01-20 | 46.60x |
| 2026-01-16 | 47.16x |
| 2026-01-15 | 46.96x |
| 2026-01-14 | 46.38x |
| 2026-01-13 | 45.62x |
| 2026-01-12 | 45.68x |
| 2026-01-09 | 47.37x |
| 2026-01-08 | 48.00x |
| 2026-01-07 | 49.01x |
| 2026-01-06 | 48.23x |
| 2026-01-05 | 46.48x |
| 2026-01-02 | 46.38x |
| 2025-12-31 | 46.60x |
| 2025-12-30 | 47.05x |
| 2025-12-29 | 47.10x |
| 2025-12-26 | 47.31x |
| 2025-12-24 | 47.34x |
| 2025-12-23 | 46.80x |
| 2025-12-22 | 47.78x |
| 2025-12-19 | 47.47x |
| 2025-12-18 | 48.00x |
| 2025-12-17 | 47.46x |
| 2025-12-16 | 47.32x |
| 2025-12-15 | 47.77x |
| 2025-12-12 | 48.45x |
| 2025-12-11 | 48.20x |
| 2025-12-10 | 48.37x |
| 2025-12-09 | 48.21x |
| 2025-12-08 | 48.53x |
| 2025-12-05 | 49.87x |
| 2025-12-04 | 51.72x |
| 2025-12-03 | 50.37x |
| 2025-12-02 | 50.60x |
| 2025-12-01 | 50.90x |
| 2025-11-28 | 53.54x |
| 2025-11-26 | 53.48x |
| 2025-11-25 | 53.81x |
| 2025-11-24 | 55.22x |
| 2025-11-21 | 54.19x |
| 2025-11-20 | 51.23x |
| 2025-11-19 | 56.64x |
| 2025-11-18 | 54.56x |
| 2025-11-17 | 53.68x |
| 2025-11-14 | 54.44x |
| 2025-11-13 | 54.43x |
| 2025-11-12 | 55.10x |
| 2025-11-11 | 53.40x |
| 2025-11-10 | 52.44x |
| 2025-11-07 | 52.35x |
| 2025-11-06 | 52.93x |
| 2025-11-05 | 55.58x |
| 2025-11-04 | 56.59x |
| 2025-11-03 | 56.33x |
| 2025-10-31 | 55.33x |
| 2025-10-30 | 55.15x |
| 2025-10-29 | 55.88x |
| 2025-10-28 | 57.29x |
| 2025-10-27 | 57.55x |
| 2025-10-24 | 56.70x |
| 2025-10-23 | 57.14x |
| 2025-10-22 | 58.14x |
| 2025-10-21 | 58.10x |
| 2025-10-20 | 57.73x |
| 2025-10-17 | 56.30x |
| 2025-10-16 | 55.90x |
| 2025-10-15 | 55.23x |
| 2025-10-14 | 56.25x |
| 2025-10-13 | 55.60x |
| 2025-10-10 | 55.59x |
| 2025-10-09 | 56.61x |
| 2025-10-08 | 55.76x |
| 2025-10-07 | 55.41x |
| 2025-10-06 | 55.10x |
| 2025-10-03 | 54.66x |
| 2025-10-02 | 55.19x |
| 2025-10-01 | 54.11x |
| 2025-09-30 | 54.59x |
| 2025-09-29 | 54.92x |
| 2025-09-26 | 56.20x |
| 2025-09-25 | 57.16x |
| 2025-09-24 | 57.75x |
| 2025-09-23 | 57.89x |
| 2025-09-22 | 59.16x |
| 2025-09-19 | 58.42x |
| 2025-09-18 | 58.89x |
| 2025-09-17 | 56.93x |
| 2025-09-16 | 58.65x |
| 2025-09-15 | 60.06x |
| 2025-09-12 | 60.32x |
| 2025-09-11 | 59.65x |
| 2025-09-10 | 59.60x |
| 2025-09-09 | 62.23x |
| 2025-09-08 | 61.67x |
| 2025-09-05 | 61.47x |
| 2025-09-04 | 61.13x |
| 2025-09-03 | 60.62x |
| 2025-09-02 | 60.86x |
| 2025-08-29 | 59.99x |
| 2025-08-28 | 59.59x |
| 2025-08-27 | 59.03x |
| 2025-08-26 | 58.59x |
| 2025-08-25 | 58.10x |
| 2025-08-22 | 58.41x |
| 2025-08-21 | 57.90x |
| 2025-08-20 | 58.80x |
| 2025-08-19 | 57.84x |
| 2025-08-18 | 57.07x |
| 2025-08-15 | 56.76x |
| 2025-08-14 | 55.81x |
| 2025-08-13 | 54.58x |
| 2025-08-12 | 54.74x |
| 2025-08-11 | 53.91x |
| 2025-08-08 | 54.30x |
| 2025-08-07 | 53.69x |
| 2025-08-06 | 61.53x |
| 2025-08-05 | 62.33x |
| 2025-08-04 | 63.81x |
| 2025-08-01 | 63.19x |
| 2025-07-31 | 63.94x |
| 2025-07-30 | 66.09x |
| 2025-07-29 | 64.62x |
| 2025-07-28 | 64.79x |
| 2025-07-25 | 64.34x |
| 2025-07-24 | 63.55x |
| 2025-07-23 | 63.57x |
| 2025-07-22 | 63.33x |
| 2025-07-21 | 62.33x |
| 2025-07-18 | 63.04x |
| 2025-07-17 | 62.87x |
| 2025-07-16 | 63.92x |
| 2025-07-15 | 64.29x |
| 2025-07-14 | 64.73x |
| 2025-07-11 | 64.14x |
| 2025-07-10 | 65.90x |
| 2025-07-09 | 65.92x |
| 2025-07-08 | 65.71x |
| 2025-07-07 | 66.62x |
| 2025-07-03 | 66.70x |
| 2025-07-02 | 66.82x |
| 2025-07-01 | 66.47x |
| 2025-06-30 | 69.55x |
| 2025-06-27 | 69.31x |
| 2025-06-26 | 68.61x |
| 2025-06-25 | 67.82x |
| 2025-06-24 | 68.84x |
| 2025-06-23 | 68.14x |
| 2025-06-20 | 67.15x |
| 2025-06-18 | 66.86x |
| 2025-06-17 | 67.42x |
| 2025-06-16 | 67.90x |
| 2025-06-13 | 67.48x |
| 2025-06-12 | 67.26x |
| 2025-06-11 | 66.96x |
Showing the most recent 260 of 1,983 data points. The chart above shows the full history.
Related Metrics
About Insulet Corp.
Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes in the United States and internationally. The company offers Omnipod platform products comprising Omnipod 5 automated insulin delivery system, which includes a proprietary AID algorithm embedded in the pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless Bluetooth communication; Omnipod DASH insulin management system that features a Bluetooth enabled pod that is controlled by a smartphone-like personal diabetes manager with a color touch screen user interface; and the Omnipod Insulin Management System. It also provides pods for Amgen for use in the Neulasta Onpro kit, which is a delivery system to help reduce the risk of infection after intense chemotherapy. The company sells its products to end-users through the pharmacy channel; and independent distributors. Insulet Corporation was incorporated in 2000 and is headquartered in Acton, Massachusetts.
- Sector
- Healthcare
- Industry
- Medical - Devices
- CEO
- Ashley A. McEvoy